Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...
Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...
Delhi: Boston Scientific Corporation, a leading medical device manufacturer, has announced the launch of its ...
for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...
Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).
In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The ...